Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Myelodysplastic Syndromes 48Multiple Myeloma 38Lymphoma 37Leukemia 35Lymphoma, Non-Hodgkin 29Leukemia, Lymphocytic, Chronic, B-Cell 24Hodgkin Disease 24Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Hematologic Neoplasms 18Lymphoma, Large B-Cell, Diffuse 16Primary Myelofibrosis 11Neuroblastoma 11Leukemia, Myelomonocytic, Chronic 11Neoplasms, Plasma Cell 10Myeloproliferative Disorders 10Graft vs Host Disease 10Lymphoma, Follicular 9Leukemia, Biphenotypic, Acute 9Burkitt Lymphoma 8Neoplasms 7Lymphoma, Mantle-Cell 7Leukemia, Myelomonocytic, Juvenile 7Breast Neoplasms 6Rhabdoid Tumor 5Recurrence 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell 5Lymphoma, B-Cell, Marginal Zone 5

Interventions

Dexamethasone 10fludarabine phosphate 9Melphalan 9fludarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Lenalidomide 7Cyclophosphamide 7Mycophenolic Acid 6Bortezomib 6Tacrolimus 5Calcium Dobesilate 4filanesib 3dexamethasone acetate 3dexamethasone 21-phosphate 3daratumumab 3carfilzomib 3auricularum 3Stem Cell Transplantation 3Sirolimus 3Filgrastim 3liposomal doxorubicin 2ixazomib 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Cytarabine 2Cyclosporine 2Carmustine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Leukemia, Plasma Cell × Stem Cell Transplantation × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT02504359 2020-11-23

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

OHSU Knight Cancer Institute

Phase 1 Completed
11 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00615589 2016-04-04

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

University of Michigan Rogel Cancer Center

Phase 2 Terminated
22 enrolled 9 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡